MRKR - Wutah dodolan YoY (TTM) markertherapeutics.com

Tandha merek Marker Therapeutics, Inc. (MRKR)

Marker Therapeutics is optimizing its biomaterial supply chains, which minimizes raw material shortages and supports profitability. The trailing twelve months (TTM) revenue change illustrates income dynamics, where -76.90 determines the current status of the parameter. Financial potential relies on the commercialization of T-cell therapies, although the high burn rate and the success of leukemia trials remain key risk factors.

MRKR - Wutah dodolan YoY sajrone rolas wulan kepungkur Marker Therapeutics Inc ing rentang 11.02.2024 - 18.11.2026

Ringkesan rincian data analitis Marker Therapeutics (MRKR)

- kuotasi saiki lan rata-rata prakiraan nilai:
Pambiji fundamental perusahaan:Marker Therapeutics Inc
Produk asil prodhuksi Marker Bio

Monitoring the dynamics of incoming cash flows is critical for assessing the issuer's financial stability. This indicator calculates the percentage deviation of total revenue over the last 12 months relative to the same window from the previous year. For Marker Therapeutics (MRKR), which scales cancer immunotherapy through grants, this calculation reflects the efficiency of attracting external funding. By analyzing the relative change in rolling year revenue versus the prior year period, an investor can determine the company's pace of commercial development.